Last reviewed · How we verify
BBIBP-CorV
At a glance
| Generic name | BBIBP-CorV |
|---|---|
| Also known as | Sinopharm, Sinopharm COVID-19 vaccine |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older (PHASE3)
- Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea (PHASE2)
- The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes
- Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals (PHASE1, PHASE2)
- Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine (PHASE3)
- A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BBIBP-CorV CI brief — competitive landscape report
- BBIBP-CorV updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI